Compare · DFTX vs USNA
DFTX vs USNA
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and USANA Health Sciences Inc. (USNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and USNA operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 23.6x USNA ($254.6M).
- Over the past year, DFTX is up 349.0% and USNA is down 56.9% - DFTX leads by 405.9 points.
- DFTX has been more active in the news (16 items in the past 4 weeks vs 5 for USNA).
- DFTX has more recent analyst coverage (7 ratings vs 3 for USNA).
- Company
- Definium Therapeutics Inc.
- USANA Health Sciences Inc.
- Price
- $44.77+3.55%
- $13.68+0.81%
- Market cap
- $6.02B
- $254.6M
- 1M return
- +4.98%
- -38.74%
- 1Y return
- +349.00%
- -56.90%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 16
- 5
- Recent ratings
- 7
- 3
USANA Health Sciences Inc.
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Latest DFTX
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest USNA
- USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
- SEC Form 10-Q filed by USANA Health Sciences Inc.
- USANA Chairman, CEO Kevin Guest Shares 5 Ways to Make Happiness Happen at Work and Home This August
- USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- USANA Health Sciences Reports Second Quarter 2026 Results
- New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
- CHIEF INFORMATION OFFICER Benedict Peter converted options into 598 shares and covered exercise/tax liability with 176 shares (SEC Form 4)
- CHIEF SCIENTIFIC OFFICER Armstrong Kathryn Michelle converted options into 1,166 shares and covered exercise/tax liability with 518 shares, increasing direct ownership by 23% to 3,471 units (SEC Form 4)
- Director Wood Timothy E converted options into 1,632 shares and covered exercise/tax liability with 408 shares, increasing direct ownership by 12% to 11,837 units (SEC Form 4)
- Director Winssinger Frederic J converted options into 1,632 shares, increasing direct ownership by 20% to 9,733 units (SEC Form 4)